BioCentury
ARTICLE | Finance

Flipping JAKs

How Cell Therapeutics flipped pacritinib to Baxter for a cash infusion

November 18, 2013 8:00 AM UTC

About 18 months after Cell Therapeutics Inc. (NASDAQ:CTIC; MILAN:CTIC) acquired pacritinib from S*BIO Pte. Ltd., CTI has flipped the myelofibrosis compound in a deal that provides a much needed cash infusion.

CTI granted Baxter International Inc. (NASDAQ:BAX) exclusive ex-U.S. commercialization rights and joint U.S. commercialization rights to the Janus kinase-2 (JAK-2) and FMS-like tyrosine kinase 3 (FLT3; CD135) inhibitor...